10 Best Cyclera Alternatives & Competitors (2026)

Schrödinger provides physics-based molecular modeling and simulation software widely used in drug discovery. Its platform emphasizes structure-based design and free-energy calculations rather than generative AI for peptide macrocycles. Compared with Menten AI, Schrödinger offers broader small-molecule and biologics tooling with established enterprise licensing but lacks Menten’s specialized de novo macrocycle generation validated at >90% hit rates for PPIs.

Insilico Medicine applies generative AI and deep learning across the full drug discovery pipeline, from target identification to clinical candidates. It focuses on small molecules and some biologics rather than peptide macrocycles. Versus Menten AI, Insilico provides end-to-end AI platforms with clinical-stage assets but does not emphasize physics-quantum hybrid optimization for oral macrocycles.

Exscientia uses AI-driven precision design to create small-molecule drugs, integrating patient tissue data and automated experimentation. Its approach centers on small molecules rather than peptide macrocycles. Relative to Menten AI, Exscientia offers broader therapeutic area coverage and automated labs but lacks Menten’s specific de novo macrocycle capabilities and reported nM potency metrics for PPIs.

Atomwise employs deep learning for structure-based small-molecule screening and design, primarily serving pharma partners. It does not specialize in generative peptide macrocycle design. Compared to Menten AI, Atomwise provides scalable virtual screening at lower cost but cannot match Menten’s physics-informed generative expansion of macrocycle chemical space.

BenevolentAI combines knowledge graphs and machine learning to generate drug hypotheses across modalities. Its platform is modality-agnostic rather than peptide-macrocycle specific. In comparison to Menten AI, BenevolentAI supports wider disease areas and data integration but lacks the targeted physics-quantum generative engine and >90% hit-rate claims for macrocycles.

Relay Therapeutics integrates computational and experimental methods focused on protein motion for small-molecule and some macrocycle programs. Its Dynamo platform emphasizes dynamic protein structures. Against Menten AI, Relay offers motion-based insights and internal pipeline assets but does not provide a standalone generative AI tool for de novo peptide macrocycles.

Peptilogics develops AI and computational platforms for peptide therapeutics, including macrocycle optimization. Its approach blends machine learning with experimental validation. Compared with Menten AI, Peptilogics offers broader peptide engineering services but does not highlight the same quantum-simulation hybrid or top-10 pharma partnership metrics for PPI targets.

Cradle applies generative AI to protein and peptide design with an emphasis on enzyme and binder engineering. It supports custom peptide sequences but is less focused on macrocycle drug properties. Relative to Menten AI, Cradle provides accessible design tools for synthetic biology use cases yet lacks Menten’s validated oral bioavailability and nM potency data for therapeutic macrocycles.

Genedata supplies enterprise software for biopharma data analysis and screening workflows. It supports high-throughput peptide and biologic programs through data management rather than generative design. In contrast to Menten AI, Genedata excels at integrating existing experimental data but does not generate new macrocycle candidates from scratch with physics-AI hybrids.